News Is BMS the next pharma takeover target? Speculation mounting that Pfizer and others could try for $90 bn plus merger
News Innate and BMS' immunotherapy fails in phase 2 trial French biotech developing cancer immunotherapy with BMS.
News Opdivo still clear immunotherapy leader despite Keytruda gai... Immunotherapy takes on rivals from Roche and BMS.
News Pfizer looks to M&A after results disappointment Pfizer is looking to deals to keep investors onside after a disappointing set of Q4 results.
News Roche's Tecentriq approved for UK early access Tecentriq is latest immunotherapy available on the scheme.
News Kite aims for Asia market with CAR-T deals in China, Japan California's Kite strikes deals with Fosun and Daiichi Sankyo.
News Isomorphic adds MSD to partner roster, and other deals It's been a busy dealmaking week, with Isomorphic Labs, fresh from a $5 billion financing, adding MSD to its list of research alliances.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.